Dr. Keila E. Torres is a Professor in Surgical Oncology at MD Anderson Cancer Center in Houston, Texas, USA. As a surgeon, Dr. Torres specializes in providing surgical care to patients with sarcoma. As a scientist, she also leads a laboratory with the primary goal of understanding how high-grade soft tissue sarcomas, such as Malignant Peripheral Nerve Sheath Tumors (MPNSTs), grow and how they can be treated more efficiently. Dr. Torres’ clinical expertise is in soft tissue sarcomas and neurofibromatosis type 1. Dr. Torres is the Co-Director of the Sarcoma Alliance for Collaboration Accelerator Program. She also serves as a scientific reviewer for the Department of Defense.
Dr. Marcio H. Malogolowkin is a Pediatric Hematologist–Oncologist in Sacramento, California, and is affiliated with multiple hospitals in the area, including Children’s Wisconsin and UC Davis Medical Center. He received his medical degree from Faculdade de Medicina da Universidade Federal do Rio de Janeiro and has been in practice for more than 20 years. Dr. Malogolowkin believes that all patients with cancer and blood diseases should be cared for like family and have access to local to top hematology–oncology experts and leading-edge treatments. He is dedicated to improving the outcomes and quality of life of his patients. Dr. Malogolowkin is board certified in pediatric hematology–oncology and cares for children, adolescents, and young adults with cancer. His areas of clinical interest are sarcomas and other rare pediatric solid tumors. His clinical research focuses on developing new comprehensive treatment protocols in pediatric solid tumors and adolescent and young adult cancers.
Dr. Ching-Hsien Chen is an Associate Professor at the University of California, Davis (UC Davis), and the Director of the Interstitial Lung Disease Biobank at the UC Davis School of Medicine. She earned her PhD in Molecular and Cellular Biology and completed postdoctoral training in Molecular Cancer Biology. Dr. Chen’s research focuses on elucidating the mechanisms of disease progression in cancer and fibrosis, with a particular emphasis on target identification and therapeutic discovery. Her work combines advanced molecular techniques with translational approaches, targeting aberrant cell signaling and metabolic reprogramming. Her research has been continuously supported by prestigious U.S. federal agencies, including the National Institutes of Health (NIH) and the Department of Defense (DoD), and has garnered recognition through numerous awards, including her designation as a UC Davis Chancellor’s Fellow. Beyond her research, Dr. Chen actively contributes to the scientific community through her participation in grant review panels and as an abstract reviewer for several international conferences. She has also served as a Guest Editor for Frontiers in Physiology and a Review Editor for Frontiers in Cell and Developmental Biology. Dr. Chen has authored numerous high-impact publications, holds multiple patents for innovative therapeutic approaches, and continues to play a pivotal role in advancing translational research for disease-targeted therapies.
